ABO-Incompatible Liver Transplantation: State of Art and Future Perspectives

Author(s): Chih-Hsien Cheng*, Chen-Fang Lee, Yu-Chao Wang, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 28 , 2020

Become EABM
Become Reviewer
Call for Editor

Abstract:

ABO-incompatible (ABO-I) liver transplantation (LT) has been limited due to the increased rate of complications, including severe cellular and antibody-mediated rejection, hepatic necrosis, hepatic artery thrombosis, and biliary complications. However, several strategies for reducing preformed anti-donor ABO antibodies and B cell desensitization have improved the outcomes of ABO-I LT. As a result, ABO-I LT has become a routine procedure and is a feasible option in countries with a scarce deceased-organ donation or in cases without an available compatible organ donor. In this review, we describe past and present desensitizing protocols as well as emergent therapies for depleting B cell and anti-ABO antibodies with the objective of identifying approaches that could lead to new, refined strategies for maximizing the results of ABO-I LT.

Keywords: ABO, incompatible, liver, transplantation, desensitization, isoagglutinin titer, rituximab, plasmapheresis.

[1]
Lee CF, Cheng CH, Wang YC, et al. Adult living donor liver transplantation across ABO-incompatibility. Medicine (Baltimore) 2015; 94(42) e1796
[http://dx.doi.org/10.1097/MD.0000000000001796] [PMID: 26496313]
[2]
Song GW, Lee SG, Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant 2016; 16(1): 157-70.
[http://dx.doi.org/10.1111/ajt.13444] [PMID: 26372830]
[3]
Lee EC, Kim SH, Park SJ. Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6516-33.
[http://dx.doi.org/10.3748/wjg.v23.i35.6516] [PMID: 29085201]
[4]
Starzl TE, Koep LJ, Halgrimson CG, et al. Fifteen years of clinical liver transplantation. Gastroenterology 1979; 77(2): 375-88.
[http://dx.doi.org/10.1016/0016-5085(79)90294-4] [PMID: 376395]
[5]
Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132(3): 489-502.
[PMID: 3046369]
[6]
Rego J, Prevost F, Rumeau JL, et al. Hyperacute rejection after ABO-incompatible orthotopic liver transplantation. Transplant Proc 1987; 19(6): 4589-90.
[PMID: 3321625]
[7]
Gordon RD, Iwatsuki S, Esquivel CO, et al. Experience with primary liver transplantation across ABO blood groups. Transplant Proc 1987; 19(6): 4575-9.
[PMID: 3321622]
[8]
Sanchez-Urdazpal L, Batts KP, Gores GJ, et al. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg 1993; 218(2): 152-8.
[http://dx.doi.org/10.1097/00000658-199308000-00006] [PMID: 8342994]
[9]
Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336(8714): 519-23.
[http://dx.doi.org/10.1016/0140-6736(90)92082-S] [PMID: 1975036]
[10]
Song GW, Lee SG, Hwang S, et al. Section 15. A desensitizing protocol without local graft infusion therapy and splenectomy is a safe and effective method in ABO-incompatible adult LDLT. Transplantation 2014; 97(Suppl. 8): S59-66.
[http://dx.doi.org/10.1097/01.tp.0000446279.81922.dd] [PMID: 24849837]
[11]
Troisi R, Noens L, Montalti R, et al. ABO-mismatch adult living donor liver transplantation using antigen-specific immunoadsorption and quadruple immunosuppression without splenectomy. Liver Transpl 2006; 12(9): 1412-7.
[http://dx.doi.org/10.1002/lt.20727] [PMID: 16528717]
[12]
Goralczyk AD, Obed A, Schnitzbauer A, et al. Adult living donor liver transplantation with abo-incompatible grafts: a German single center experience. J Transplant 2009; 2009, 759581
[http://dx.doi.org/10.1155/2009/759581] [PMID: 20148072]
[13]
Kim JD, Choi DL, Han YS. Fourteen successful consecutive cases of ABO-incompatible living donor liver transplantation: new simplified intravenous immunoglobulin protocol without local infusion therapy. Transplant Proc 2014; 46(3): 754-7.
[http://dx.doi.org/10.1016/j.transproceed.2013.11.100] [PMID: 24767341]
[14]
Uchiyama H, Mano Y, Taketomi A, et al. Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. Transplantation 2011; 92(10): 1134-9.
[http://dx.doi.org/10.1097/TP.0b013e318231e9f8] [PMID: 21946174]
[15]
Ikegami T, Yoshizumi T, Soejima Y, Uchiyama H, Shirabe K, Maehara Y. Feasible usage of ABO incompatible grafts in living donor liver transplantation. Hepatobiliary Surg Nutr 2016; 5(2): 91-7.
[PMID: 27115002]
[16]
Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 7-12.
[http://dx.doi.org/10.1182/asheducation.V2012.1.7.3797920] [PMID: 23233554]
[17]
Mörtzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: An update of the WAA registry data. Transfus Apheresis Sci 2016; 54(1): 2-15.
[http://dx.doi.org/10.1016/j.transci.2016.01.003] [PMID: 26776481]
[18]
Szczeklik W, Wawrzycka K, Włudarczyk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther 2013; 45(1): 7-13.
[http://dx.doi.org/10.5603/AIT.2013.0002] [PMID: 23572301]
[19]
Tanabe K. Double-filtration plasmapheresis. Transplantation 2007; 84(12)(Suppl.): S30-2.
[http://dx.doi.org/10.1097/01.tp.0000296103.34735.b8] [PMID: 18162985]
[20]
Egawa H, Teramukai S, Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant 2014; 14(1): 102-14.
[http://dx.doi.org/10.1111/ajt.12520] [PMID: 24279828]
[21]
Alexandre G, Squifflet J-P, De Bruyere M. Splenectomy as perquisite for successful human ABO incompatible renal transplantation 1985.
[22]
Squifflet JP, De Meyer M, Malaise J, Latinne D, Pirson Y, Alexandre GP. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2004; 2(1): 208-13.
[PMID: 15859930]
[23]
Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007; 84(12)(Suppl.): S33-6.
[http://dx.doi.org/10.1097/01.tp.0000296122.19026.0f] [PMID: 18162986]
[24]
Raut V, Mori A, Kaido T, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012; 93(1): 99-105.
[http://dx.doi.org/10.1097/TP.0b013e318239e8e4] [PMID: 22094955]
[25]
Ito K, Akamatsu N, Ichida A, et al. Splenectomy is not indicated in living donor liver transplantation. Liver Transpl 2016; 22(11): 1526-35.
[http://dx.doi.org/10.1002/lt.24489] [PMID: 27253521]
[26]
Golse N, Mohkam K, Rode A, Pradat P, Ducerf C, Mabrut JY. Splenectomy during whole liver transplantation: a morbid procedure which does not adversely impact long-term survival. HPB (Oxford) 2017; 19(6): 498-507.
[http://dx.doi.org/10.1016/j.hpb.2017.01.020] [PMID: 28233673]
[27]
Tanabe M, Shimazu M, Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002; 73(12): 1959-61.
[http://dx.doi.org/10.1097/00007890-200206270-00021] [PMID: 12131697]
[28]
Kawachi S, Shimazu M, Wakabayashi G, et al. Efficacy of intraportal infusion of prostaglandin E1 to improve the hepatic blood flow and graft viability in porcine liver transplantation. Transplantation 1997; 64(2): 205-9.
[http://dx.doi.org/10.1097/00007890-199707270-00004] [PMID: 9256174]
[29]
Strom TB, Carpenter CB Jr, Cragoe EJ Jr, Norris S, Devlin R, Perper RJ. Suppression of in vivo and in vitro alloimmunity by prostaglandins. Transplant Proc 1977; 9(1): 1075-9.
[PMID: 325735]
[30]
Moran M, Mozes MF, Maddux MS, et al. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med 1990; 322(17): 1183-8.
[http://dx.doi.org/10.1056/NEJM199004263221703] [PMID: 2109195]
[31]
Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY: [ethyl P-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980; 19(4-5): 579-88.
[http://dx.doi.org/10.1016/0049-3848(80)90030-4] [PMID: 6449757]
[32]
Kim BW, Park YK, Kim YB, Wang HJ, Kim MW. Effects and problems of adult ABO-incompatible living donor liver transplantation using protocol of plasma exchange, intra-arterial infusion therapy, and anti-CD20 monoclonal antibody without splenectomy: case reports of initial experiences and results in Korea. Transplant Proc 2008; 40(10): 3772-7.
[http://dx.doi.org/10.1016/j.transproceed.2008.03.174] [PMID: 19100487]
[33]
Yoshizawa A, Sakamoto S, Ogawa K, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005; 37(4): 1718-9.
[http://dx.doi.org/10.1016/j.transproceed.2005.03.148] [PMID: 15919443]
[34]
Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47(1): 143-52.
[http://dx.doi.org/10.1002/hep.21928] [PMID: 17929298]
[35]
Tanabe M, Kawachi S, Obara H, et al. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest 2010; 40(10): 943-9.
[http://dx.doi.org/10.1111/j.1365-2362.2010.02339.x] [PMID: 20636381]
[36]
Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13(9): 954-66.
[http://dx.doi.org/10.1634/theoncologist.2008-0089] [PMID: 18779537]
[37]
Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012; 61(8): 1233-41.
[http://dx.doi.org/10.1007/s00262-011-1168-2] [PMID: 22249775]
[38]
Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54(8): 2377-86.
[http://dx.doi.org/10.1002/art.22019] [PMID: 16869000]
[39]
van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100(6): 2257-9.
[http://dx.doi.org/10.1182/blood.V100.6.2257] [PMID: 12200395]
[40]
Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B. Rituximab with plasmapheresis and splenectomy in abo-incompatible liver transplantation. Transplantation 2003; 76(11): 1648-9.
[http://dx.doi.org/10.1097/01.TP.0000082723.02477.87] [PMID: 14702545]
[41]
Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97(1): 101-6.
[http://dx.doi.org/10.1182/blood.V97.1.101] [PMID: 11133748]
[42]
Egawa H, Umeshita K, Uemoto S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation. J Hepatobiliary Pancreat Sci 2017; 24(2): 89-94.
[http://dx.doi.org/10.1002/jhbp.419] [PMID: 28002655]
[43]
Yamamoto H, Uchida K, Kawabata S, et al. Feasibility of monotherapy by rituximab without additional desensitization in ABO-incompatible living-donor liver transplantation. Transplantation 2018; 102(1): 97-104.
[http://dx.doi.org/10.1097/TP.0000000000001956] [PMID: 28938311]
[44]
Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-508.
[http://dx.doi.org/10.4254/wjh.v7.i11.1494] [PMID: 26085909]
[45]
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13(3): 176-89.
[http://dx.doi.org/10.1038/nri3401] [PMID: 23411799]
[46]
Shen T, Lin BY, Jia JJ, et al. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. HBPD INT 2014; 13(4): 395-401.
[http://dx.doi.org/10.1016/S1499-3872(14)60268-X] [PMID: 25100124]
[47]
Kim SH, Lee EC, Shim JR, Park SJ. A simplified protocol using rituximab and immunoglobulin for ABO-incompatible low-titre living donor liver transplantation. Liver Int 2017.
[PMID: 29053910]
[48]
Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107(4): 387-93.
[http://dx.doi.org/10.1046/j.1365-2567.2002.01545.x] [PMID: 12460182]
[49]
Kimball JA, Pescovitz MD, Book BK, Norman DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60(12): 1379-83.
[http://dx.doi.org/10.1097/00007890-199560120-00001] [PMID: 8545860]
[50]
Karnell JL, Karnell FG III, Stephens GL, et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 2011; 187(7): 3603-12.
[http://dx.doi.org/10.4049/jimmunol.1003319] [PMID: 21873529]
[51]
Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin Transplant 2007; 21(1): 24-31.
[http://dx.doi.org/10.1111/j.1399-0012.2006.00572.x] [PMID: 17302588]
[52]
Hwang S, Song GW, Jung DH, et al. Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy. Ann Hepatobiliary Pancreat Surg 2017; 21(1): 11-6.
[http://dx.doi.org/10.14701/ahbps.2017.21.1.11] [PMID: 28317040]
[53]
Langers P, Press RR, Inderson A, et al. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. Ther Drug Monit 2014; 36(2): 141-7.
[http://dx.doi.org/10.1097/FTD.0b013e3182a37a1e] [PMID: 24081208]
[54]
Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol 2012; 30: 39-68.
[http://dx.doi.org/10.1146/annurev-immunol-020711-075024] [PMID: 22136167]
[55]
De Simone P, Fagiuoli S, Cescon M, et al. Use of everolimus in liver transplantation: recommendations from a working group. Transplantation 2017; 101(2): 239-51.
[http://dx.doi.org/10.1097/TP.0000000000001438] [PMID: 27495768]
[56]
Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant 2014; 2014, 845438
[http://dx.doi.org/10.1155/2014/845438] [PMID: 24719752]
[57]
Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011; 24(12): 1216-30.
[http://dx.doi.org/10.1111/j.1432-2277.2011.01357.x] [PMID: 21955006]
[58]
Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14(2): 356-66.
[http://dx.doi.org/10.1111/ajt.12543] [PMID: 24456026]
[59]
Saliba F, De Simone P, Nevens F, et al. H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13(7): 1734-45.
[http://dx.doi.org/10.1111/ajt.12280] [PMID: 23714399]
[60]
Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12(11): 1640-8.
[http://dx.doi.org/10.1002/lt.20707] [PMID: 16598777]
[61]
Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10(10): 2252-62.
[http://dx.doi.org/10.1111/j.1600-6143.2010.03128.x] [PMID: 20486905]
[62]
Holdaas H, De Simone P, Zuckermann A. Everolimus and malignancy after solid organ transplantation: a clinical update. J Transplant 2016; 2016, 4369574
[http://dx.doi.org/10.1155/2016/4369574] [PMID: 27807479]
[63]
Toso C, Al-Qahtani M, Alsaif FA, et al. ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int 2007; 20(8): 675-81.
[http://dx.doi.org/10.1111/j.1432-2277.2007.00492.x] [PMID: 17521384]
[64]
Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3(1): 50-2.
[http://dx.doi.org/10.1034/j.1600-6143.2003.30109.x] [PMID: 12492710]
[65]
ter Meulen CG, Baan CC, Hené RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001; 72(10): 1709-10.
[http://dx.doi.org/10.1097/00007890-200111270-00027] [PMID: 11726840]
[66]
Kim JM, Kwon CH, Joh JW, et al. Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation. Br J Surg 2016; 103(3): 276-83.
[http://dx.doi.org/10.1002/bjs.10048] [PMID: 26695115]
[67]
Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev 2014; (6): CD010253
[http://dx.doi.org/10.1002/14651858.CD010253.pub2] [PMID: 24901467]
[68]
Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006; 6(8): 1913-21.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01406.x] [PMID: 16771811]
[69]
Zhang GQ, Zhang CS, Sun N, Lv W, Chen BM, Zhang JL. Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials. HBPD INT 2017; 16(2): 139-46.
[http://dx.doi.org/10.1016/S1499-3872(16)60183-2] [PMID: 28381376]
[70]
Lin CC, Chuang FR, Lee CH, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11(10): 1258-64.
[http://dx.doi.org/10.1002/lt.20520] [PMID: 16184544]
[71]
Lawrence C, Galliford JW, Willicombe MK, et al. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011; 92(10): 1129-33.
[http://dx.doi.org/10.1097/TP.0b013e31823360cf] [PMID: 21959216]
[72]
Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7(2): 402-7.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01632.x] [PMID: 17241113]
[73]
Voorhees PM, Dees EC, O’Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9(17): 6316-25.
[PMID: 14695130]
[74]
Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9(1): 201-9.
[http://dx.doi.org/10.1111/j.1600-6143.2008.02461.x] [PMID: 18976291]
[75]
Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86(12): 1754-61.
[http://dx.doi.org/10.1097/TP.0b013e318190af83] [PMID: 19104417]
[76]
Ensor CR, Yousem SA, Marrari M, et al. Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. Am J Transplant 2017; 17(5): 1380-8.
[http://dx.doi.org/10.1111/ajt.14222] [PMID: 28173620]
[77]
Gerlach UA, Schoenemann C, Lachmann N, Koch M, Pascher A. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Transpl Int 2011; 24(5): e43-5.
[http://dx.doi.org/10.1111/j.1432-2277.2010.01203.x] [PMID: 21155900]
[78]
Lee CF, Eldeen FZ, Chan KM, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc 2012; 44(2): 529-31.
[http://dx.doi.org/10.1016/j.transproceed.2012.01.051] [PMID: 22410063]
[79]
Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3(7): 1017-23.
[PMID: 12186261]
[80]
Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9(1): 231-5.
[http://dx.doi.org/10.1111/j.1600-6143.2008.02451.x] [PMID: 18976298]
[81]
Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11(11): 2405-13.
[http://dx.doi.org/10.1111/j.1600-6143.2011.03757.x] [PMID: 21942930]
[82]
Glotz D, Russ G, Rostaing L, et al. Eculizumab in prevention of acute antibody-mediated rejection in sensitized deceased-donor kidney transplant recipients: 1-year outcomes. Am J Transplant 2015; 15(Suppl. 3): 3039.
[83]
West-Thielke P, Progar K, Campara M, et al. Eculizumab for prevention of antibody-mediated rejection in blood group-incompatible renal transplantation. Transplant Proc 2018; 50(1): 66-9.
[http://dx.doi.org/10.1016/j.transproceed.2017.12.015] [PMID: 29407333]
[84]
Irving CA, Gennery AR, Carter V, et al. ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers. J Heart Lung Transplant 2015; 34(8): 1095-102.
[http://dx.doi.org/10.1016/j.healun.2015.03.013] [PMID: 26116516]
[85]
Dawson KL, Parulekar A, Seethamraju H. Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 2012; 31(12): 1325-6.
[http://dx.doi.org/10.1016/j.healun.2012.09.016] [PMID: 23063321]
[86]
Fan J, Tryphonopoulos P, Tekin A, et al. Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient. Am J Transplant 2015; 15(7): 1995-2000.
[http://dx.doi.org/10.1111/ajt.13183] [PMID: 25649227]
[87]
Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived c1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 2016; 16(12): 3468-78.
[http://dx.doi.org/10.1111/ajt.13871] [PMID: 27184779]
[88]
Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest 2015; 45(4): 423-40.
[http://dx.doi.org/10.1111/eci.12419] [PMID: 25678219]
[89]
Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86(19): 7547-51.
[http://dx.doi.org/10.1073/pnas.86.19.7547] [PMID: 2798426]
[90]
Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17(9): 2381-9.
[http://dx.doi.org/10.1111/ajt.14228] [PMID: 28199785]
[91]
Roddy JV, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma 2016; 57(1): 81-5.
[http://dx.doi.org/10.3109/10428194.2015.1045896] [PMID: 26140610]
[92]
Vo AA, Choi J, Kim I, et al. A Phase I/II Trial of the Interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 2015; 99(11): 2356-63.
[http://dx.doi.org/10.1097/TP.0000000000000741] [PMID: 26018350]
[93]
von Pawel-Rammingen U, Björck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol 2003; 6(1): 50-5.
[http://dx.doi.org/10.1016/S1369-5274(03)00003-1] [PMID: 12615219]
[94]
Jordan SC, Lorant T, Choi J. IgG Endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377(17): 1693-4.
[http://dx.doi.org/10.1056/NEJMoa1612567] [PMID: 29083132]
[95]
Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 2017; 34(2): 324-56.
[http://dx.doi.org/10.1007/s12325-016-0451-1] [PMID: 28004361]
[96]
Byrd JC, Flynn JM, Kipps TJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016; 127(1): 79-86.
[http://dx.doi.org/10.1182/blood-2015-03-634394] [PMID: 26472752]
[97]
Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377(14): 1331-44.
[http://dx.doi.org/10.1056/NEJMoa1614598] [PMID: 28976863]
[98]
Redfield R, Jordan S, Schindler T, et al. Emerging safety and tolerability of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of renal transplant candidates. Am J Transplant 2017; 17((suppl 3)).
[99]
Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2(7): 465-75.
[http://dx.doi.org/10.1038/nri844] [PMID: 12094221]
[100]
Snanoudj R, Candon S, Roelen DL, et al. Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation. Transplantation 2014; 97(9): 917-24.
[http://dx.doi.org/10.1097/01.TP.0000438211.34842.5e] [PMID: 24827764]
[101]
Banham G, Prezzi D, Harford S, et al. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 2013; 96(4): 413-20.
[http://dx.doi.org/10.1097/TP.0b013e318298dd65] [PMID: 23842189]
[102]
Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-52.
[http://dx.doi.org/10.1146/annurev.immunol.19.1.225] [PMID: 11244036]
[103]
Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10(3): 535-46.
[http://dx.doi.org/10.1111/j.1600-6143.2009.03005.x] [PMID: 20415897]
[104]
Durrbach A, Pestana JM, Florman S, et al. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant 2016; 16(11): 3192-201.
[http://dx.doi.org/10.1111/ajt.13830] [PMID: 27130868]
[105]
Inaba A, Watson C, Clatworthy M, Torpey N. Belatacept used as rescue maintenance immunosuppression in ABO-incompatible living donor kidney transplant. Transplantation 2012; 94: 753.
[http://dx.doi.org/10.1097/00007890-201211271-01474]
[106]
Kwun J, Burghuber C, Manook M, et al. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Adv 2017; 1(24): 2115-9.
[http://dx.doi.org/10.1182/bloodadvances.2017010991] [PMID: 29296858]
[107]
Ygberg S, Nilsson A. The developing immune system - from foetus to toddler. Acta Paediatr 2012; 101(2): 120-7.
[http://dx.doi.org/10.1111/j.1651-2227.2011.02494.x] [PMID: 22003882]
[108]
Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974; 14(6): 551-9.
[http://dx.doi.org/10.1111/j.1537-2995.1974.tb04576.x] [PMID: 4432260]
[109]
McGreal EP, Hearne K, Spiller OB. Off to a slow start: under development of the complement system in term newborns is more substantial following premature birth. Immunobiology 2012; 217(2): 176-86.
[http://dx.doi.org/10.1016/j.imbio.2011.07.027] [PMID: 21868122]
[110]
Esquivel CO, Koneru B, Karrer F, et al. Liver transplantation before 1 year of age. J Pediatr 1987; 110(4): 545-8.
[http://dx.doi.org/10.1016/S0022-3476(87)80545-0] [PMID: 3550022]
[111]
Stewart ZA, Locke JE, Montgomery RA, Singer AL, Cameron AM, Segev DL. ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. Liver Transpl 2009; 15(8): 883-93.
[http://dx.doi.org/10.1002/lt.21723] [PMID: 19642117]
[112]
Egawa H, Oike F, Buhler L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77(3): 403-11.
[http://dx.doi.org/10.1097/01.TP.0000110295.88926.5C] [PMID: 14966415]
[113]
Honda M, Sugawara Y, Kadohisa M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation. Transplantation 2018; 102(10): 1702-9.
[http://dx.doi.org/10.1097/TP.0000000000002197] [PMID: 29620615]
[114]
Kasahara M, Umeshita K, Inomata Y, Uemoto S. Japanese Liver Transplantation Society. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. Am J Transplant 2013; 13(7): 1830-9.
[http://dx.doi.org/10.1111/ajt.12276] [PMID: 23711238]
[115]
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391(10127): 1301-14.
[http://dx.doi.org/10.1016/S0140-6736(18)30010-2] [PMID: 29307467]
[116]
Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9(7): 684-92.
[http://dx.doi.org/10.1053/jlts.2003.50147] [PMID: 12827553]
[117]
Chen CH, Chen YY, Chen GH, et al. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol 2004; 40(4): 653-9.
[http://dx.doi.org/10.1016/j.jhep.2003.12.002] [PMID: 15030982]
[118]
Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44(Suppl. 19): 102-7.
[http://dx.doi.org/10.1007/s00535-008-2251-0] [PMID: 19148802]
[119]
Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018; 24(1): 1-9.
[http://dx.doi.org/10.3350/cmh.2017.0112] [PMID: 29249129]
[120]
Lee SD, Kim SH, Kong SY, Kim YK, Park SJ. Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transpl Immunol 2015; 32(1): 29-34.
[http://dx.doi.org/10.1016/j.trim.2014.11.216] [PMID: 25449537]
[121]
Yoon YI, Song GW, Lee SG, et al. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. J Hepatol 2018; 68(6): 1153-62.
[http://dx.doi.org/10.1016/j.jhep.2018.02.002] [PMID: 29452208]
[122]
Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996; 16(4): 415-25.
[http://dx.doi.org/10.1055/s-2007-1007254] [PMID: 9027954]
[123]
Moon DB, Lee SG, Kang WH, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high-model for end stage liver disease score patients. Am J Transplant 2017; 17(7): 1833-42.
[http://dx.doi.org/10.1111/ajt.14198] [PMID: 28097804]
[124]
Mendes M, Ferreira AC, Ferreira A, et al. ABO-incompatible liver transplantation in acute liver failure: a single Portuguese center study. Transplant Proc 2013; 45(3): 1110-5.
[http://dx.doi.org/10.1016/j.transproceed.2013.02.012] [PMID: 23622639]
[125]
Yasuda M, Ikegami T, Imai D, et al. The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure. J Med Invest 2015; 62(3-4): 184-7.
[http://dx.doi.org/10.2152/jmi.62.184] [PMID: 26399345]
[126]
Bang JB, Kim BW, Kim YB, et al. Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation. World J Gastroenterol 2016; 22(30): 6925-35.
[http://dx.doi.org/10.3748/wjg.v22.i30.6925] [PMID: 27570428]
[127]
Song GW, Lee SG, Hwang S, et al. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. J Hepatol 2014; 61(3): 575-82.
[http://dx.doi.org/10.1016/j.jhep.2014.04.039] [PMID: 24801413]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 28
Year: 2020
Published on: 31 August, 2020
Page: [3406 - 3417]
Pages: 12
DOI: 10.2174/1381612826666200506094539
Price: $65

Article Metrics

PDF: 47
HTML: 4